# Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

> **NCT04775745** · PHASE1 · RECRUITING · sponsor: **Newave Pharmaceutical Inc** · enrollment: 60 (estimated)

## Conditions studied

- CLL/SLL
- Waldenstrom Macroglobulinemia
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Hairy Cell Leukemia

## Interventions

- **DRUG:** LP-168
- **DRUG:** LP-168

## Key facts

- **NCT ID:** NCT04775745
- **Lead sponsor:** Newave Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-19
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775745, "Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04775745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*